Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Notes Payables (2016 - 2025)

China Pharma Holdings filings provide 12 years of Notes Payables readings, the most recent being $1.4 million for Q4 2025.

  • On a quarterly basis, Notes Payables rose 25.34% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 25.34% increase, with the full-year FY2025 number at $1.4 million, up 25.34% from a year prior.
  • Notes Payables hit $1.4 million in Q4 2025 for China Pharma Holdings, up from $1.4 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $4.6 million in Q3 2022 to a low of $315428.0 in Q3 2024.
  • Median Notes Payables over the past 5 years was $1.4 million (2025), compared with a mean of $1.7 million.
  • Biggest five-year swings in Notes Payables: crashed 84.44% in 2024 and later skyrocketed 348.07% in 2025.
  • China Pharma Holdings' Notes Payables stood at $1.2 million in 2021, then surged by 222.25% to $3.8 million in 2022, then plummeted by 70.16% to $1.1 million in 2023, then rose by 0.99% to $1.1 million in 2024, then grew by 25.34% to $1.4 million in 2025.
  • The last three reported values for Notes Payables were $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.